Circulating Sphingosine-1-Phosphate as A Non-Invasive Biomarker of Heart Transplant Rejection

Estefanía Tarazón1, Carolina Gil-Cayuela1, María García Manzanares2, Marta Roca3, Francisca Lago4, José Ramón González-Juanatey4, Elena Sánchez-Lacuesta5, Luis Martínez-Dolz1,6, Manuel Portolés1,6 & Esther Roselló-Lletí1

Accumulating evidence has confirmed that the expression of sarcoplasmic reticulum calcium ATPase 2a (SERCA2a) is downregulated in heart failure and cardiac allograft rejection. Although many SERCA2a-related genes and proteins involved in the regulation of myocardial Ca2+ fluxes have been explored, its related metabolites remain poorly studied. Our main objective was to identify circulating SERCA2a-related metabolites altered in cardiac allograft rejection and to determine whether these could serve as non-invasive biomarkers. Sixty plasma samples from adult heart transplant were included in a metabolomic analysis. Sphingosine-1 phosphate (S1P), metabolite closely related with SERCA, were increased in patients with cardiac rejection ($p < 0.0001$). S1P discriminated between patients with and without rejection: normal grafts vs. all rejecting grafts ($AUC = 0.911$, $p < 0.0001$), normal grafts vs. Grade 1 R ($AUC = 0.819$, $p < 0.0001$), Grade 2 R ($AUC = 0.819$, $p < 0.0001$), Grade 3 R ($AUC = 0.996$, $p < 0.0001$). In addition, we found changes in key enzymes and receptors of S1P pathway analysed on explanted hearts from heart failure patients. This preliminary study reveals that circulating S1P determination could be a novel approach to detect cardiac rejection, showing a robust capability for detection that improves gradually with the severity of rejection. These alterations could be relevant to better understand the involvement of calcium regulation on the pathophysiology of rejection.

Graft rejection is a leading cause of death after transplant1. Endomyocardial biopsy (EMB) is the standard rejection screening procedure but presents relevant risks for patients and has technical limitations2,3. Although effective alternatives have been studied for years4–12, non-invasive monitoring of rejection remains a challenge. Imaging techniques and use of peripheral blood biomarkers have greatly progressed, however some of them have shown poor diagnostic precision or have complex execution. Further studies are needed to establish a simple and non-invasive alternative for detecting heart graft rejection, and reveal the pathophysiological mechanisms for preventing and treating this condition.

Sarcoplasmic reticulum calcium ATPase 2a (SERCA2a) has received central attention because of its critical role in regulating calcium cycling, being abnormal Ca2+ cycling a primary cause of cardiac dysfunction13. This molecule is also a relevant target in gene therapy for heart failure. Gene therapy and gene delivery methods have shown significant progress, and the results from important trials confirm the need of further investigation13–17.

1Myocardial Dysfunction and Cardiac Transplantation Unit, Health Research Institute Hospital La Fe (IIS La Fe); and CIBERCV, M.P., Avd. Fernando Abril Martorell, 106, 46026, Valencia, Spain. 2Medicine and Animal Surgery, CEU Cardenal Herrera University, C/Tirant lo Blanc, 7, 46115 Alfara del Patriarca, Valencia, Spain. 3Analytical Unit, Health Research Institute Hospital La Fe (IIS La Fe), Avd. Fernando Abril Martorell, 106, 46026, Valencia, Spain. 4Cellular and Molecular Cardiology Research Unit, Department of Cardiology and Institute of Biomedical Research, University Clinical Hospital; and CIBERCV, M.P., Travesía de Choupana, s/n, 15706, Santiago de Compostela, Spain. 5Hemodynamic Unit, Cardiology Department, University and Polytechnic La Fe Hospital, Avd. Fernando Abril Martorell, 106, 46026, Valencia, Spain. 6Heart Failure and Transplantation Unit, Cardiology Department, University and Polytechnic La Fe Hospital, Avd. Fernando Abril Martorell, 106, 46026, Valencia, Spain. Manuel Portolés and Esther Roselló-Lletí contributed equally. Correspondence and requests for materials should be addressed to E.R.-L. (email: esther_rosello_lleti@hotmail.com)
Furthermore, it is involved in cardiac allograft rejection; we previously demonstrated that SERCA2a serum levels change during heart rejection\(^\text{10}\). These findings suggest that SERCA2a concentration assessment may be a relatively simple, capable and non-invasive test for detecting heart transplant rejection. Although many SERCA2a-related genes and proteins involved in the regulation of myocardial Ca\(^{2+}\) fluxes have been explored in heart disease\(^\text{18,19}\), few related metabolites have been studied. Specifically, we previously observed partial translocation of nitric oxide by nitric oxide synthase 1 (NOS1) to the sarcolemma in ischemic hearts\(^\text{19}\) and that the upregulation of cardiac NOS1 is not accompanied by increased NOS1 activity in dilated cardiomyopathy\(^\text{20}\). This SERCA2a-related protein may be significant in the pathophysiology of human ischemic and dilated heart disease with a preservative role in maintaining myocardial homeostasis. Given the importance of this pathway, an in-depth understanding of its biologic role is necessary to find potential avenues for a continuous improvement of diagnosis and treatment.

Metabolomics is an emerging science that analyses the metabolome in complex biological systems by combining sensitive analytical techniques\(^\text{21}\). The use of metabolomics in clinical cardiac approaches has the potential to identify new diagnostic and/or prognostic biomarkers for improving the ability to understand pathophysiological pathways related to cardiac allograft rejection. We conducted a metabolomic study with the objective of identifying plasma SERCA2a-related metabolites altered in cardiac allograft rejection. We identified sphingosine-1-phosphate (S1P), a metabolite related with SERCA2a, as a potential non-invasive marker of cardiac rejection, highlighting the involvement of calcium-handling in the rejection process. In addition, we analysed the S1P pathway through the mRNA determination of the key enzymes in the S1P generation and breakdown and also its receptors on explanted hearts from patients with heart failure.

Results

All groups of post-transplant patients included in the metabolic study were similar regarding variables such as age, gender, body mass index, diabetes mellitus, dyslipidaemia, echo-Doppler measurements, and hemodynamic parameters. However, we found a higher percentage of patients with hypertension and an increase in lymphocyte number and NT-proBNP and Troponin T levels in the groups with rejection (Table 1).

After data pre-processing in positive and negative ESI modes, overall metabolic differences between non-rejection and rejection groups were evaluated. Better separation between groups was obtained for the negative ionization mode. PCA analysis showed a trend of inter-group separation between the non-rejection group and Grades 2 R and 3 R (Fig. 1A,B). OPLS-DA score plots (Fig. 1C,D) showed a clear discrimination between the non-rejection group and Grades 2 R and 3 R (with Q2Y > 0.5 and CV-ANOVA \(p < 0.01\), in all models). No separation was observed between non-rejection group and Grade 1 R (Supplemental Fig. 1). From the non-rejection group vs. Grades 2 R and 3 R discriminant analysis, we built a variance importance in projection (VIP) plot, summarizing the contribution that each variable makes to the discriminant model. Those variables with VIP > 1 were considered relevant for group discrimination and selected for identification and comparison with those selected in the initial statistical analysis.

As shown in Table 2 we identify thirteen differential metabolites, but only S1P levels showed statistically significant differences between the group of patients without rejection and each group of rejection. Then, we focused on S1P, a metabolite closely related with SERCA2a, as have been reported by other authors’ previously\(^\text{22,23}\). In this study we support this relationship since we have found an inverse significant correlation \(r = -0.47, p < 0.0001\), Supplementary Fig. 2) between the circulating levels of the S1P and SERCA2a (SERCA2a circulating levels obtained in our previous study)\(^\text{10}\). In addition, we have obtained a significant correlation between S1P levels and lymphocyte number \(r = 0.425, p < 0.01\).

S1P identity was confirmed by comparing MS/MS spectra and retention time of the chemical standard with plasma samples (Fig. 2). S1P plasma levels were higher in patients with heart transplant rejection \(p < 0.0001\), Fig. 3A). When compared patients without allograft rejection with patients of Grade 1 R, 2 R, and 3 R independently, and with 2 R and 3 R combined, we found significant differences for all comparisons (Fig. 3B–E). Additionally, we observed significant differences between Grade 1 R and 2 R \(p < 0.05\), Grade 1 R and 3 R \(p < 0.0001\), and Grade 2 R and 3 R \(p < 0.01\).

ROC curves were performed to analyse the capability of S1P for detecting heart transplant rejection (all grades combined) obtaining a significant area under the curve \(0.911 \pm 0.040\) (95% CI, 0.833–0.988); \(p < 0.0001\) (Fig. 3F). When we divided the heart transplant rejection group into different grades, we observed that S1P detection capability improves in higher grades. For Grade 1 R \(0.819 \pm 0.078\) (95% CI, 0.666–0.972); \(p < 0.01\), for Grade 2 R \(0.911 \pm 0.054\) (95% CI, 0.805–1.000); \(p < 0.0001\), for Grade 3 R \(0.996 \pm 0.007\) (95% CI, 0.981–1.000); \(p < 0.0001\), and for Grade 2 R and 3 R combined \(0.953 \pm 0.030\) (95% CI, 0.895–1.000); \(p < 0.0001\) (Fig. 3G–J). The sensitivity, specificity, positive predictive value, and negative predictive value for the diagnosis of rejection are summarized in Table 3.

In light of the relevant results described above, we further investigate on S1P pathway in heart failure. We analysed the mRNA expression of the enzymes involved in S1P synthesis and breakdown, and S1P receptors on cardiac tissue from heart failure patients (Table 4). We obtained a significant decrease in S1P phosphatase 1 (SGPP1, \(p < 0.05\)) and 2 (SGPP2, \(p < 0.01\)) levels. S1P receptor 3 levels (S1PR3, \(p < 0.05\)) were also downregulated in patients when we compared with control samples.

Discussion

Although the gold standard for the diagnosis of cardiac allograft rejection is the EMB, this procedure may have negative consequences for the patient. Its invasive nature causes patient discomfort and carries the risk of potentially life-threatening complications, including cardiac perforation, tamponade, and arrhythmias\(^\text{3}\). In addition, EMB is subject to sampling error and inter-observer variability\(^\text{3}\). Due to these important risks and limitations, numerous studies have been focused on finding non-invasive monitoring of acute and chronic rejection after
cardiac transplantation. Overall, these studies demonstrated insufficient diagnostic accuracy, limited sensitivity at lower grades of rejection, limited positive predictive value, and their implementation has been proved complex and in some cases relatively expensive.

This metabolomic study reveals that assessment of plasma S1P allows accurate discrimination between patients with allograft rejection, and those without. We found an increase in S1P levels in peripheral blood in rejection groups, with a capability for detection that improved gradually as rejection grades increased. Our results suggest that S1P has clinical interest as a non-invasive biomarker of heart transplant rejection. Although we have found several phospholipids and other metabolites altered when we compared the different groups of study, we focused on S1P since this sphingolipid is the only altered in the three rejection groups analysed and is also involved in Ca2+ regulation.

Sphingolipids such as S1P have been recognized as important second messengers. S1P is a well-known survival factor in many tissues, and has been given substantial attention to obtain additional mechanistic insight into its signalling and biological activity in the cardiovascular system. This metabolite has a greater predictive value in detecting coronary artery disease, than traditional risk factors. In the cardiovascular system, ceramides are catabolized by ceramidase to produce sphingosine which is phosphorylated by Sphingosine kinases 1 and 2 (SPHK1 and SPHK2) to generate the signal transmitter S1P. This molecule is either dephosphorylated by SGPPs and broken down by S1P lyase 1 (SGPL1). When we have evaluated these enzymes on cardiac tissue from heart failure patients we observed a decrease of mRNA levels. These findings along with the fact of not finding changes in SPHKs and SGPI suggest a S1P accumulation in these pathological samples. In fact, previous studies have demonstrated that inhibition of SGPP1 increase S1P accumulation and that SGPP1 overexpression is indicative of reduced S1P signalling. S1P is a mediator of ischemic pre- and post-conditioning, with S1P receptors being expressed in the myocardium, endothelium, and platelets. In this study, although we detect mRNA expression of the five S1P receptors in cardiac tissue from heart failure patients, we only observed a significant downregulation in S1PR3. In accordance with our results, previous works have shown the S1PR1 and S1PR3 to be the predominant S1P receptor subtype on cardiac tissue

| Table 1. Patient characteristics at the time of biopsy and blood sample extraction. LV, left ventricular; NT-proBNP, N-terminal fragment of B-type natriuretic peptide. |
|---|---|---|---|---|---|---|
| | Non-rejection (n=15) | Rejection (n=45) | Grade 1 R (n=15) | Grade 2 R (n=15) | Grade 3 R (n=15) | p-value |
| Age, years | 53 ± 12 | 50 ± 12 | 50 ± 12 | 51 ± 11 | 48 ± 14 | 0.757 |
| Male sex (%) | 80 | 93 | 93 | 100 | 87 | 0.309 |
| Indication for cardiac transplantation | | | | | | |
| Ischemic cardiomyopathy (%) | 20 | 41 | 57 | 33 | 60 | 0.168 |
| Idiopathic dilated cardiomyopathy (%) | 60 | 41 | 29 | 33 | 60 | 0.168 |
| Other (%) | 20 | 18 | 14 | 33 | 7 | 0.290 |
| Time between transplantation and study enrolment, months | 5.6 ± 3.9 | 4.2 ± 3.6 | 5.4 ± 3.9 | 4.0 ± 3.8 | 3.3 ± 2.9 | 0.281 |
| Body mass index (kg/m²) | 26 ± 5 | 23 ± 4 | 24 ± 4 | 21 ± 3 | 25 ± 4 | 0.105 |
| Hypertension (%) | 7 | 46 | 50 | 47 | 40 | 0.049 |
| Diabetes mellitus (%) | 27 | 50 | 71 | 33 | 47 | 0.077 |
| Dyslipemia (%) | 47 | 30 | 50 | 20 | 21 | 0.177 |
| Echo-Doppler study | | | | | | |
| Ejection fraction (%) | 64 ± 9 | 61 ± 6 | 57 ± 8 | 67 ± 6 | 69 ± 4 | 0.102 |
| LV end systolic diameter (mm) | 27 ± 4 | 27 ± 4 | 27 ± 4 | 28 ± 5 | 27 ± 3 | 0.945 |
| LV end diastolic diameter (mm) | 44 ± 4 | 44 ± 4 | 43 ± 4 | 45 ± 4 | 43 ± 3 | 0.853 |
| Hemodynamic parameters | | | | | | |
| Mean right atrial pressure (mm Hg) | 7.1 ± 3.7 | 6.8 ± 3.9 | 6.1 ± 5.0 | 7.5 ± 3.2 | 6.9 ± 3.1 | 0.818 |
| Systolic right ventricular pressure (mm Hg) | 33 ± 16 | 29 ± 16 | 34 ± 11 | 36 ± 8 | 37 ± 8 | 0.802 |
| Diastolic right ventricular pressure (mm Hg) | 7.3 ± 4.1 | 6.6 ± 3.7 | 5.8 ± 4.1 | 6.9 ± 3.3 | 7.6 ± 4.0 | 0.730 |
| Immunosuppressive therapy | | | | | | |
| Tacrolimus (%) | 100 | 100 | 100 | 100 | 100 | — |
| Mycophenolic acid (%) | 100 | 98 | 100 | 93 | 100 | 0.394 |
| Steroids (%) | 100 | 98 | 100 | 93 | 100 | 0.394 |
| Neutrophils (thousands/mm³) | 4.5 ± 2.7 | 5.6 ± 4.6 | 4.6 ± 4.0 | 6.1 ± 4.8 | 6.3 ± 5.2 | 0.550 |
| Leukocytes (thousands/mm³) | 6.6 ± 2.8 | 8.1 ± 4.7 | 6.6 ± 3.8 | 8.4 ± 5.0 | 9.3 ± 5.2 | 0.272 |
| Lymphocytes (thousands/mm³) | 1.4 ± 0.45 | 1.7 ± 0.8 | 1.4 ± 0.4 | 1.5 ± 0.6 | 2.2 ± 1.1 | 0.003 |
| Hemoglobin (mg/dL) | 11.8 ± 2.3 | 12.3 ± 1.8 | 12.5 ± 1.2 | 12.5 ± 2.0 | 11.8 ± 2.2 | 0.658 |
| Hematocrit (%) | 37 ± 7 | 38 ± 5 | 39 ± 3 | 39 ± 6 | 37 ± 6 | 0.615 |
| NT-proBNP (pg/mL) | 200 ± 85 | 1441 ± 3449 | 2267 ± 5721 | 715 ± 519 | 1266 ± 1246 | 0.001 |
| Troponin T (ng/L) | 13 ± 7 | 60 ± 98 | 73 ± 134 | 62 ± 57 | 37 ± 26 | 0.049 |
Interestingly, previous reports support that sphingosine could control the activity of SERCA, hence this sphingolipid participate in the regulation of Ca\(^{2+}\) through its inhibitory effect on Ca\(^{2+}\)-ATPase activity. These authors showed a direct interaction of sphingosine with the Ca\(^{2+}\)-ATPase\(^{22}\). In addition, S1P are reported to trigger endoplasmic reticulum stress\(^{31}\) and ceramide disrupts Ca\(^{2+}\) homeostasis by inhibiting SERCA expression, thus also increasing endoplasmic reticulum stress\(^{32}\). In this sense, our results are in concordance with the previous findings since we have found an inverse correlation between the blood levels of SERCA2a and S1P being altered in opposite direction when the patients present cardiac rejection and finding an inverse relationship between both molecules. Our previous results demonstrated that levels of circulating SERCA2a allow precise discrimination between patients with allograft rejection and those without (Grade 1 R AUC = 0.751, Grade 2 R AUC = 0.875, Grade 3 R AUC = 0.922), being SERCA2a serum levels lower in the rejection groups\(^{10}\). Now, we have obtained relevant findings in the same direction, even with an improved capability of rejection. S1P plasma levels were higher in patients with heart transplant rejection and presented a strong rejection detection capability, especially in clinically relevant rejection degrees (Grade 2 R AUC = 0.911, Grade 3 R AUC = 0.996), showing excellent sensitivity, specificity, and positive and negative predictive values. S1P strongly discriminated between patients with allograft rejection Grade 1 R and patients without rejection (AUC = 0.819). In addition, we observed differences in NT-proBNP levels between patients with and without allograft rejection. However, the levels of this peptide did not enable for distinctions between different grades of rejection, suggesting that while NT-proBNP is a factor mirroring an established tissue damage, S1P might change according to damage progression and involvement of vascular component. Taken all together, our findings demonstrate the direct involvement of myocardial calcium homeostasis alterations not only in heart failure condition but also on the physiopathological mechanism leading to cardiac rejection. This disorder is reflected in peripheral blood and discriminates with excellent accuracy between patients with allograft rejection and those without, showing a solid capability for detection that improves in the most clinically relevant rejection degrees.

Improvements towards clinical implementation of new markers are laborious and costly, and meta-analyses and prospective validation are also necessary. In fact, Gene Expression Profiling (Allomap) is the only non-invasive diagnostic test included in International Society for Heart and Lung Transplantation (ISHLT) guidelines to identify the risk of acute cellular rejection in heart transplant recipients. However, it lacks a good positive predictive value and it can only be used to rule out the presence of acute cellular rejection of grade 2 R or greater in appropriate low-risk patients. In addition, AlloMap is specific to acute cellular rejection and cannot diagnose patients with humoral rejection\(^{35}\). Consequently, a novel set of biomarkers is greatly required to complement these assays in order to detect organ injury and improve routine clinical practice. New studies focused on to identify circulating microRNAs\(^3\), serum exosomal proteins\(^4\), cell-free DNA (cfDNA)\(^5\) or individual biomarkers\(^6,7\) as effective and non-invasive diagnostic procedures are emerging with significant results. However, their precise role in mediating rejection remains to be elucidated requiring more work. In addition, pre-transplant assessment of S1P could be necessary to determine its predictive value. The possibility to detect individuals at high risk of early acute rejection before transplantation would make it possible to better surveillance of these patients in order to reduce the risk of late complications.

**Figure 1.** Score plots from PCA and OPLS-DA analysis. PCA score plot (−) ESI mode for normal vs. Grade 2 R (A); PCA score plot (−) ESI mode for normal vs. Grade 3 R (B); OPLS-DA score plot (−) ESI mode for normal vs. Grade 2 R (C); OPLS-DA score plot (−) ESI mode for normal vs. Grade 3 R (D).
| Mass (m/z) | RT (min) | Detection mode | Formula | Adduct | Compound name | Tentative | Confirmed | p-value | Grade 0 R vs. 1 R | Grade 0 R vs. 2 R | Grade 0 R vs. 3 R |
|-----------|----------|----------------|---------|--------|---------------|-----------|-----------|---------|-----------------|-----------------|-----------------|
| 158.9788  | 0.53     | –              | C5H11AsO2 | M-H2O-H| Arsenobetaine | NS        | *< 0.0001 | < 0.0001 |
|           |          |                | C5H5ClN2S | M-H    | 5-Chloro-3-cyclopropyl-1,2,4-thiadiazole | NS        |           |         |
|           |          |                | C5H5ClN2S | M-H    | 2-Chloro-6-(methylsulfanyl)pyrazine | NS        |           |         |
|           |          |                | C5H5ClN2S | M-H    | 4-Chloro-6-(methylsulfanyl)pyrimidine | NS        |           |         |
|           |          |                | C5H5ClN2S | M-H    | 2-Chloro-4-(methylsulfanyl)pyrimidine | NS        |           |         |
|           |          |                | C5H5ClN2S | M-H    | 5-Chloro-2-(methylthio)pyrimidine | NS        |           |         |
|           |          |                | C5H5ClN2S | M-H    | 4-Chloro-2-methylthiopyrimidine | NS        |           |         |
|           |          |                | C5H5ClN2S | M-H    | 3-Chloro-6-(methylthio)pyridazine | NS        |           |         |
|           |          |                | C5H5ClN2S | M-H    | 3-Aminothiophene-2-carbonitrile hydrochloride | NS        |           |         |
| 215.0662  | 0.66     | –              | C8H14N2O6 | M-H2O-H| L-beta-aspartyl-l-threonine | NS        | < 0.05   | < 0.01  |
|           |          |                | C8H14N2O6 | M-H    | Aspartyl-threonine | NS        |           |         |
|           |          |                | C8H14N2O6 | M-H    | Threoninyl-aspartate | NS        |           |         |
| 234.8864  | 12.95    | +              | C3H6S6  | M+H    | 1,2,4,5,7,8-hexathionane | NS        | NS       | < 0.05  |
|           |          |                | C3H6S6  | M+H    | 1,2,3,5,6,8-Hexathionane | NS        | NS       | < 0.05  |
|           |          |                | C6H3Cl3O| M+K    | 2,4,6-trichlorophenol | NS        |           |         |
|           |          |                | C6H3Cl3O| M+K    | 2,4,5-trichlorophenol | NS        |           |         |
| 261.1311  | 3.35     | +              | C12H20O6| M+H    | Glycerol tripropanoate | NS        | NS       | < 0.05  |
| 378.2410  | 7.94     | –              | C18H40O6 | M-H2O-H| Phytosphingosine-1-p | Sphingosine 1-phosphate | < 0.01   | < 0.0001 |
| 464.3010  | 6.54     | –              | C26H44O6| M+H    | Glycocholic acid | NS        | NS       | < 0.05  |
| 476.2775  | 8.39     | –              | C23H46N7P| M-H    | LysoPE(0:0/18:2(9z,12z)) | LysoPE(18:2(9z,12z)/0:0) | < 0.05   | < 0.01  |
|           |          |                | C23H46N7P| M-H    | LysoPE(18:1(9z)/0:0) | LysoPE(18:1(11z)/0:0) | NS       |         |
| 517.3886  | 9.45     | –              | C31H52O3| M+FA-H | Soyasapogenol D | 3,4-dihydroxymethane-6-yl acetate | < 0.05   | < 0.05  |
|           |          |                | C31H52O3| M+FA-H | [2,5,7,8-Tetramethyl-2-(4,8,12-trimethyltridecyl)] | NS        |           |         |
|           |          |                | C32H50N9P| M-H    | Ganoderol c |             |           |         |
| 526.3133  | 8.36     | –              | C23H48N7P| M+FA-H | LysoPC(15:0) | LysoPC(18:0/18:0) | NS       | < 0.01  |
|           |          |                | C23H48N7P| M+FA-H | LysoPE(0:0/18:0) | LysoPE(18:0/18:0) | NS       |         |
|           |          |                | C24H48N7P| M+FA-H | LysoPC(16:1(9z)) | LysoPC(19:1(9z)) | NS       |         |
|           |          |                | C24H48N7P| M+FA-H | (2-aminoethoxy)[(2 R)-3-hydroxy-2-[(9Z)-nonadec-9-enoyloxy]propoxy]phosphinic acid | LysoPC(18:0/18:1(11z)) | NS       |         |
|           |          |                | C25H50N9P| M-H    | PE(10:0/10:0(3-oh)) | PE(10:0/10:0(3-oh)) | < 0.05   | < 0.05  |
| Mass (m/z) | RT (min) | Detection mode | Formula | Adduct | Compound name | p-value | Confirmed | Grade 0 R vs. 1 R | Grade 0 R vs. 2 R | Grade 0 R vs. 3 R |
|-----------|----------|----------------|---------|--------|---------------|---------|-----------|------------------|------------------|------------------|
| 588.3301  | 8.40     | —              | C28H50NO7P | M+FA-H | LysoPC(20:4(5z,8z,11z,14z)) | NS      | NS        | <0.05            |                  |                  |
| 606.3011  | 8.20     | —              | C31H41N7O6 | M-H    | chymostatin    | NS      | NS        | <0.001           |                  |                  |
| 749.5389  | 10.33    | +              | C28H50NO7P | M+FA-H | LysoPC(20:4(5z,8z,11z,14z,17z)) | NS      | NS        |                  |                  |                  |
|           |          |                | C28H50NO7P | M+FA-H | LysoPC(20:4(5z,8z,11z,14z,17z)) |         |           |                  |                  |                  |
|           |          |                | C28H52NO12P| M-H2O-H| 2-amino-3-[[2(R)-3-[[3-hydroxydecanoyl]oxy]-2-|         |           |                  |                  |                  |
|           |          |                |         |        | oxo)propionate|         |           |                  |                  |                  |
|           |          |                | C28H52NO12P| M-H2O-H| 2-amino-3-[[2(R)-3-[[3-hydroxydecanoyl]oxy]-2-|         |           |                  |                  |                  |
|           |          |                |         |        | oxo)propionate|         |           |                  |                  |                  |
|           |          |                |         |        |                 |         |           |                  |                  |                  |

Table 2. Metabolomics identifies differential metabolites between patients without allograft rejection (Grade 0 R) and patients with allograft rejection (Grade 1 R, 2 R, 3 R). RT, retention time.

This metabolomic study reveals that assessment of plasma S1P allows accurate discrimination between patients with allograft rejection, and those without. We found an increase in S1P levels in peripheral blood in rejection groups, with a capability for detection that improved gradually as rejection grades increased. Our results suggest that S1P has clinical interest as a relatively simple, non-invasive biomarker in the diagnosis of heart transplant rejection. However, we show a preliminary study with a limited number of subjects per group that may be validated in larger prospective patient cohorts to contribute to a better investigation on cardiac rejection and lead to the use of this non-invasive determination as an alternative to EMB in the detection of rejection. In this sense, the discovery of precise markers of cardiac rejection like the previously cited, and now S1P as new candidate, could allow the possibility of establishing improved panels for pre- and post-transplantation surveillance.

Our study is limited on several points and the results must be interpreted in this context. Because systemic and myocardial metabolism can change rapidly in response to conditions such as stress or diet, the present study did not address the changes in patient metabolic profiles at different time points. For better data interpretation, the dynamics and stability of metabolomic profiles need to be well-known. Furthermore, our tissue samples are confined to transmural left ventricle apex and we do not discriminate the tissue component such as vessels or lymphocyte infiltration; thus, our findings could not be generalized to all regions of the left ventricle and we cannot specify the precise origin of the alterations found. In addition, this work represents the involvement of one single centre and it is focused on cellular rejection and have not specifically evaluated antibody-mediated rejection, a relevant clinical entity of rejection associated with worse graft survival. However, the current analyses provide valuable information, and these limiting factors could be the goals for future studies.

In conclusion, this preliminary study reveals that circulating S1P determination could be a novel approach to detect cardiac rejection, showing a robust capability for detection that improves gradually with the severity of rejection. The alteration of this SERCA-related metabolite could be relevant to understand better the involvement of calcium regulation on the pathophysiology of transplant rejection.

Methods

Collection of samples. The metabolomic study included sixty heart transplant patients (>18 years) from a single centre, University and Polytechnic La Fe Hospital, who were referred for EMB as a scheduled routine screening. Hearts used in the transplants were no procured from prisoners, organs were donated by people who communicated to their families the desire to be donors, and those authorized the removal of organs after death, all of them came from hospitals of the Spanish National Health System. At the time of EMB, blood samples were collected for laboratory analysis. Plasma was separated by centrifugation at 1500xg for 10 minutes at 4 °C, aliquoted, and immediately stored at −80 °C. Study participants were divided into 4 groups: patients transplanted without allograft rejection (Grade 0 R n=15), and 3 subsets of patients with biopsy-proven allograft rejection (Grade 1 R n=15, Grade 2 R n=15, Grade 3 R n=15). In order to compare groups with each other, the same sample size was established for all groups, so that patients were consecutively included according to their Grade until the number of patients per group was equal.

Patients were maintained on a standard immunosuppression regimen, and rejection episodes were assessed according to the International Society for Heart and Lung Transplantation (ISHLT) consensus report. For each sample, we recorded age, gender, body mass index, primary heart disease, interval between transplantation and study enrolment, biochemical markers, echocardiographic parameters, and other clinical characteristics at the time of each biopsy (Table 1). Experimenters were blind to group assignment and outcome assessment, for all experiments.

The study was approved by the Ethics Committee (Biomedical Investigation Ethics Committee of La Fe University Hospital of Valencia, Spain) and was conducted in accordance with the principles outlined in the Declaration of Helsinki. Prior to sample collection, signed informed consent was obtained from each patient.
Metabolomic analysis. Chemicals reagents, plasma processing and analysis using UPLC-QToF-MS-based untargeted metabolomics, and quality control assurance are included as Supporting Information.

MS data pre-processing and metabolite identification. Acquired raw files were converted into mzXML format using Proteowizard 3.0 (http://proteowizard. Sourceforge.net/). Data processing was done through our in-house R-script with the XCMS package (https://bioconductor.org/packages/release/bioc/html/xcms.html). The CAMERA package (https://bioconductor.org/packages/release/bioc/html/CAMERA.html) was also used for identification of isotopes and probable adducts. Finally, a data matrix was generated including variables (m/z-retention time), sample ID (observations), and peak intensities. Before statistical analysis, metabolites with a coefficient of variation >30% of their QC values were filtered out.

Metabolite identification of selected variables was performed by query of the exact mass of detected features against the online Human Metabolome Database (HMDB) (http://www.hmdb.ca/) and the Metlin database (https://metlin.scripps.edu) within a specific mass range (±10 ppm). The identity of the metabolites of interest was confirmed by comparing the MS/MS spectra of the selected features with those of the proposed metabolites in the cited online databases. The identity of the selected metabolite was further confirmed by using authentic standards (sphingosine-1-phosphate, Sigma-Aldrich, Madrid, Spain).

RNA sequencing analysis. We also included an RNA sequencing (RNAseq) study to analyse the main enzymes and receptors of S1P pathway on twenty-six explanted hearts from heart failure patients undergoing cardiac transplantation and and ten age- and gender matched non-diseased donor hearts. Left ventricular samples were collected from near the apex of the left ventricle and maintained in 0.9% NaCl at 4 °C for a maximum of 4.4 ± 3 h after the coronary circulation loss, and then stored at −80 °C until RNA extraction. The appropriate handling and rapid sample collection and storage by our on call (24 h) team, lead to the collection of these high quality samples (RNA Integrity Number (RIN) >9 for all samples). Clinical history, electrocardiogram, and Doppler echocardiography data were available on patients.4,15,18 All controls (CNT) had normal left ventricular function (left ventricular ejection fraction >50%), and no history of cardiac disease. CNT samples were obtained from non-diseased donor hearts that had been rejected for cardiac transplantation owing to size or blood type incompatibility. CNT died of either cerebrovascular or motor vehicle accidents.

Methods used for RNA extraction, RNAseq, computational analysis, and gene functional annotation of the RNAseq data were performed as previously described15,18. The data presented in this publication have been deposited in the NCBI Gene Expression Omnibus (GEO) and can be retrieved using http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE55296 (GEO Series accession number GSE55296).
Statistical analysis. Basal characteristics were expressed as mean ± standard deviation for continuous variables, and percentages for discrete variables. Results for each variable were tested for normality using the Kolmogorov-Smirnov method. Continuous variables not following a normal distribution were compared using

---

**Figure 3.** Circulating levels of S1P between non-rejection and rejection heart allografts and receiver-operating characteristic (ROC) curves. Comparison between non-rejection vs. all grades of rejection heart allografts (A). Comparison between the different grades of rejection heart allografts (B,C,D). Comparison between non-rejection vs. Grade 2 R and 3 R combined (E). The middle line in boxplots represents the median, the lower box bound the first quartile, the upper box bound the third quartile, the whiskers the 95% confidence interval of the fourth mean. ROC curve of circulating S1P for the detection of cardiac allograft rejection: All grades (F), Grade 1 R (G), Grade 2 R (H), Grade 3 R (I). Grade 2 R and 3 R combined (J). *p < 0.01, **p < 0.0001.
Table 3. Sensitivities, specificities, and predictive values for the diagnosis of cardiac rejection. PPV, positive predictive value; NPV, negative predictive value.

| Grade | Cutoff point (au) | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) |
|-------|------------------|----------------|-----------------|--------|---------|
| Grade 1 R | 6211 | 93 | 47 | 62 | 78 |
| Grade 2 R | 6780 | 93 | 73 | 73 | 92 |
| Grade 3 R | 10554 | 93 | 100 | 100 | 94 |
| Grade 1 R, 2 R, and 3 R combined | 6613 | 93 | 67 | 89 | 77 |
| Grade 2 R and 3 R combined | 7031 | 93 | 87 | 93 | 87 |

Table 4. mRNA expression levels of S1P-related genes involved in S1P pathway in heart failure and control hearts. Data are showed as the mRNA expression levels (arbitrary units) ± standard deviation.

| Gene name | Description | Function | Heart failure hearts (n=26) | Control hearts (n=10) | p-value |
|-----------|-------------|----------|---------------------------|----------------------|---------|
| S1PR1 | Sphingosine 1-phosphate receptor 1 | S1P receptor activity | 480 ± 126 | 574 ± 393 | 0.474 |
| S1PR2 | Sphingosine 1-phosphate receptor 2 | S1P receptor activity | 1.83 ± 1.6 | 5.02 ± 8.74 | 0.271 |
| S1PR3 | Sphingosine 1-phosphate receptor 3 | S1P receptor activity | 80 ± 40 | 143 ± 77 | 0.033 |
| S1PR4 | Sphingosine 1-phosphate receptor 4 | S1P receptor activity | 2.17 ± 2.01 | 3.60 ± 5.32 | 0.431 |
| S1PR5 | Sphingosine 1-phosphate receptor 5 | S1P receptor activity | 3.18 ± 3.02 | 2.65 ± 3.46 | 0.653 |
| SphK1 | Sphingosine kinase 1 | S1P generation | 30 ± 16 | 36 ± 31 | 0.562 |
| SphK2 | Sphingosine kinase 2 | S1P generation | 40 ± 16 | 32 ± 14 | 0.214 |
| SGPP1 | Sphingosine 1-phosphate phosphatase 1 | S1P dephosphorylation | 41 ± 14 | 61 ± 39 | 0.045 |
| SGPP2 | Sphingosine 1-phosphate phosphatase 2 | S1P dephosphorylation | 16 ± 13 | 45 ± 31 | 0.016 |
| SGPL1 | Sphingosine 1-phosphate lyase 1 | S1P breakdown | 140 ± 53 | 172 ± 65 | 0.586 |

The Mann–Whitney test, and categorical clinical variables were compared using the chi-square test. Variables with a normal distribution were compared using the Student’s t-test for continuous variables, and the Fisher’s exact test for discrete variables.

The sensitivity, specificity, and predictive value of plasma S1P levels for the presence of transplant rejection was assessed by construction of receiver-operating characteristic (ROC) curves. A p <0.05 was considered statistically significant. All statistical analyses were performed using SPSS software (version 20.0; IBM SPSS Inc; Chicago, IL, USA).

Multivariate data analysis (MVDA) of processed data was performed using Simca 14.1 software (Sartorius Stedim Biotech, Aubagne, France). Pareto scaling was used for data scaling. An unsupervised descriptive Principal Component Analysis (PCA) was carried out to provide an overview of the data, observe clustering and trends, and identify strong outliers. Supervised orthogonal-least-squares-discriminant (OPLS-DA) models were used to identify pattern related metabolites, relate metabolic profiles to rejection factors, and confirm patterns observed with PCA. The quality and significance of the supervised models was assessed using the predicted variation in Y (Q2Y) calculated from 7-fold cross-validation, and the CV-ANOV A p-value, both calculated using SIMCA software.

References
1. Stehlík, J. et al. The Registry of the International Society for Heart and Lung Transplantation: 29th official adult heart transplant report—2012. J Heart Lung Transplant. 31, 1052–1064 (2012).
2. Berghersen, L. et al. Adverse event rates in congenital cardiac catheterization - a multi-center experience. Catheter Cardiovasc Interv. 75, 389–400 (2010).
3. Nielsen, H. et al. Reproducibility of the acute rejection diagnosis in human cardiac allografts. The Stanford Classification and the International Grading System. J Heart Lung Transplant. 12, 239–243 (1993).
4. Park, M. H., Scott, R. L., Uber, P. A. & Mehra, M. R. Bedside b-type natriuretic peptide and acute non-cellular cardiac allograft rejection. J Heart Lung Transplant. 21, 613–614 (2002).
5. Miller, C. A. et al. Non-invasive approaches for the diagnosis of acute cardiac allograft rejection. Heart. 99, 445–453 (2013).
6. Mullen, C. J. et al. Troponin T and I are not reliable markers of cardiac transplant rejection. Eur J Cardiothorac Surg. 22, 233–237 (2002).
7. Crespo-Leiro, M. G. et al. Clinical usefulness of gene-expression profile to rule out acute rejection after heart transplantation: CARGO II. Eur Heart J. 37, 2591–2601 (2016).
8. Duong Van Huyen, J. P. et al. MicroRNAs as non-invasive biomarkers of heart transplant rejection. Eur Heart J. 35, 3194–3202 (2014).
9. Kennel, P. I. et al. Serum exosomal protein profiling for the non-invasive detection of cardiac allograft rejection. J Heart Lung Transplant. 37, 409–417 (2018).
10. Tarczón, E. et al. SERCA2a: A potential non-invasive biomarker of cardiac allograft rejection. J Heart Lung Transplant. 36, 1322–1328 (2017).
11. Aghor-Enoh, S. et al. Applying rigor and reproducibility standards to assay donor-derived cell-free DNA as a non-invasive method for detection of acute rejection and graft injury after heart transplantation. J Heart Lung Transplant. 36, 1094–1012 (2017).
12. Crescioli, C. The role of immunological biomarkers in cardiac rejection. Curr Opin Organ Transplant. 18, 595–600 (2013).
13. Hajjar, R. J. et al. Modulation of ventricular function through gene transfer in vivo. Proc Natl Acad Sci USA 95, 5251–5256 (1998).
14. Jaski, B. E. et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. *J Card Fail*. 15, 171–181 (2009).

15. Jessup, M. et al. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intra coronary gene therapy of sarco/pilomatrix reticulum Ca2+-ATPase in patients with advanced heart failure. *Circulation*. 124, 304–313 (2011).

16. Greenberg, B. et al. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID-2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. *Lancet*. 387, 1178–1186 (2016).

17. Greenberg, B. et al. Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure. *Gene Ther*. 23, 313–319 (2016).

18. Stüdeli, R. et al. Diastolic dysfunction in human cardiac allografts is related with reduced SERCA2a gene expression. *Am J Transplant*. 6, 775–782 (2006).

19. Roselló-Lleti, E., Lépine, S., Gómez-González, J. R. et al. Human Ischemic Cardiomyopathy Shows Cardiac Nos1 Translocation and its Increased Levels Are Related to Left Ventricular Performance. *Sci Rep*. 6, 24060 (2016).

20. Roselló-Lleti, E. et al. Protein Inhibitor of Nos1 Plays a Central Role in the Regulation of Nos1 Activity in Human Dilated Hearts. *Sci Rep*. 6, 30902 (2016).

21. Lewis, G. D., Asnani, A. & Gerszten, R. E. Application of metabolomics to cardiovascular biomarker and pathway discovery. *J Am Coll Cardiol*. 52, 117–123 (2008).

22. Colina, C., Cervino, V. & Benaim, G. Ceramide and sphingosine have an antagonistic effect on the plasma-membrane Ca2+-ATPase from human erythrocytes. *Biochim J*. 362, 247–251 (2002).

23. Benaim, G. et al. Sphingosine inhibits the sarco(endoplasmic reticulum Ca(2+-)-ATPase (SERCA) activity. *Biochem Biophys Res Commun.* 473, 572–577 (2016).

24. Cannavo, A. et al. Sphingosine Kinases and Sphingosine 1-Phosphate Receptors: Signaling and Actions in the Cardiovascular System. *Front Pharmacol*. 8, 556 (2017).

25. Deutschman, D. H. et al. Predicting obstructive coronary artery disease with serum sphingosine-1-phosphate. *Am Heart J*. 146, 62–68 (2003).

26. Ogretmen, B. Sphingolipid metabolism in cancer signalling and therapy. *Nat Rev Cancer*. 18, 33–50 (2018).

27. Gao, X. Y. et al. Inhibition of sphingosine-1-phosphate phosphatase 1 promotes cancer cells migration in gastric cancer: Clinical implications. *Oncol Rep*. 34, 1977–1987 (2015).

28. Johnson, K. R. et al. Role of human sphingosine-1-phosphate phosphatase in the regulation of intra- and extracellular sphingosine-1-phosphate levels and cell viability. *J Biol Chem*. 278, 34541–34547 (2003).

29. Kall learner, J. S., Honbo, N., Summers, K., Gray, M. O. & Goetzl, E. J. The lysophospholipids sphingosine-1-phosphate and lysophosphatidic acid enhance survival during hypoxia in neonatal rat cardiac myocytes. *J Cell Sci*. 111, e0168302 (2016).

30. Lewis, G. D., Asnani, A. & Gerszten, R. E. Application of metabolomics to cardiovascular biomarker and pathway discovery. *J Am Coll Cardiol*. 52, 117–123 (2008).

31. Lépine, S. et al. Sphingosine-1-phosphate phosphohydrolase-1 regulates ER stress-induced autophagy. *Cell Death Differ*. 18, 350–361 (2011).

32. Liu, Z. et al. Induction of ER stress-mediated apoptosis by ceramide via disruption of ER Ca(2+) homeostasis in human adenoid cystic carcinoma cells. *Cell Biosci*. 4, 71 (2014).

33. Costanzo, M. R. International Society of Heart and Lung Transplantation Guidelines. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. *J Heart Lung Transplant*. 29, 914–56 (2010).

34. Colvin, M. M. Antibody-mediated rejection in cardiac transplantation: emerging knowledge in diagnosis and management: a scientific statement from the American Heart Association. *Circulation*. 131(1608–39), 8 (2015).

35. Stewart, S. et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. *J Heart Lung Transplant*. 24, 1710–1720 (2005).

36. Macrae, D. J. The Council for International Organizations and Medical Sciences (CIOMS) guidelines on ethics of clinical trials. *Proc Am Thorac Soc*. 4, 176–178 (2007).

Acknowledgements

We are grateful to Bankia and Levante-EMV for the Award and financial support given to Esther Roselló-Lleti, “Young Talent Award 2017” in the category of Science. This work was supported by the National Institute of Health “Fondo de Investigaciones Sanitarias del Instituto de Salud Carlos III” [PI16/01627, PI17/01925, PI17/01232], “Consorcio Centro de Investigación Biomédica en Red, M.P.” [CIBERCV, under Grant CB16/11/00261], and the European Regional Development Fund (FEDER). The funders did not have a specific role in the manuscript development.

Author Contributions

E.R.L. conceived the original idea, supervised the project and wrote the main manuscript text. E.R.L. and M.P. planned the experiments. E.S.L. provided the samples. E.T. and C.G.C. collected and processed the samples. E.T., C.G.C., M.G.M. and M.R. carried out the experiments. E.L., J.R.G.J., L.M.D. and M.P. contributed to interpretation of results. All authors contributed to the final version of the manuscript.

Additional Information

Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-50413-8.

Competing Interests: The authors declare no competing interests.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2019